|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HLA-DRB5 |
Gene summary for HLA-DRB5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HLA-DRB5 | Gene ID | 3127 |
| Gene name | major histocompatibility complex, class II, DR beta 5 | |
| Gene Alias | HLA-DRB5* | |
| Cytomap | 6p21.32 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q30154 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3127 | HLA-DRB5 | GSM4909282 | Human | Breast | IDC | 5.86e-03 | 1.25e-01 | -0.0288 |
| 3127 | HLA-DRB5 | GSM4909293 | Human | Breast | IDC | 5.53e-28 | 5.35e-01 | 0.1581 |
| 3127 | HLA-DRB5 | GSM4909300 | Human | Breast | IDC | 5.59e-15 | 6.64e-01 | 0.0334 |
| 3127 | HLA-DRB5 | GSM4909317 | Human | Breast | IDC | 1.19e-02 | 1.83e-01 | 0.1355 |
| 3127 | HLA-DRB5 | GSM4909319 | Human | Breast | IDC | 3.07e-03 | 2.24e-01 | 0.1563 |
| 3127 | HLA-DRB5 | M1 | Human | Breast | IDC | 5.19e-06 | 2.67e-01 | 0.1577 |
| 3127 | HLA-DRB5 | M2 | Human | Breast | IDC | 8.33e-06 | 6.44e-01 | 0.21 |
| 3127 | HLA-DRB5 | NCCBC11 | Human | Breast | DCIS | 9.38e-04 | 6.10e-01 | 0.1232 |
| 3127 | HLA-DRB5 | NCCBC3 | Human | Breast | DCIS | 4.28e-36 | 9.20e-01 | 0.1198 |
| 3127 | HLA-DRB5 | NCCBC5 | Human | Breast | DCIS | 4.66e-13 | 6.63e-01 | 0.2046 |
| 3127 | HLA-DRB5 | P2 | Human | Breast | IDC | 6.85e-15 | 7.45e-01 | 0.21 |
| 3127 | HLA-DRB5 | CA_HPV_1 | Human | Cervix | CC | 3.68e-23 | -7.82e-01 | 0.0264 |
| 3127 | HLA-DRB5 | CA_HPV_2 | Human | Cervix | CC | 2.54e-21 | -7.98e-01 | 0.0391 |
| 3127 | HLA-DRB5 | CA_HPV_3 | Human | Cervix | CC | 1.43e-22 | -7.93e-01 | 0.0414 |
| 3127 | HLA-DRB5 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 1.66e-08 | -3.76e-01 | 0.0208 |
| 3127 | HLA-DRB5 | N_HPV_1 | Human | Cervix | N_HPV | 2.35e-21 | -7.60e-01 | 0.0079 |
| 3127 | HLA-DRB5 | N_HPV_2 | Human | Cervix | N_HPV | 2.56e-18 | -7.12e-01 | -0.0131 |
| 3127 | HLA-DRB5 | CCI_1 | Human | Cervix | CC | 4.28e-09 | -8.58e-01 | 0.528 |
| 3127 | HLA-DRB5 | CCI_2 | Human | Cervix | CC | 2.64e-08 | -8.58e-01 | 0.5249 |
| 3127 | HLA-DRB5 | CCI_3 | Human | Cervix | CC | 1.02e-04 | -7.08e-01 | 0.516 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00198862 | Stomach | CSG | antigen processing and presentation of exogenous peptide antigen via MHC class II | 13/1034 | 30/18723 | 2.05e-09 | 2.47e-07 | 13 |
| GO:00025042 | Stomach | CSG | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 14/1034 | 36/18723 | 2.72e-09 | 3.07e-07 | 14 |
| GO:00025012 | Stomach | CSG | peptide antigen assembly with MHC protein complex | 10/1034 | 18/18723 | 7.37e-09 | 7.09e-07 | 10 |
| GO:00023992 | Stomach | CSG | MHC class II protein complex assembly | 9/1034 | 16/18723 | 3.71e-08 | 2.89e-06 | 9 |
| GO:00025032 | Stomach | CSG | peptide antigen assembly with MHC class II protein complex | 9/1034 | 16/18723 | 3.71e-08 | 2.89e-06 | 9 |
| GO:00224072 | Stomach | CSG | regulation of cell-cell adhesion | 48/1034 | 448/18723 | 8.67e-06 | 3.05e-04 | 48 |
| GO:004578521 | Stomach | CSG | positive regulation of cell adhesion | 47/1034 | 437/18723 | 9.72e-06 | 3.36e-04 | 47 |
| GO:00421102 | Stomach | CSG | T cell activation | 48/1034 | 487/18723 | 7.39e-05 | 1.78e-03 | 48 |
| GO:00071592 | Stomach | CSG | leukocyte cell-cell adhesion | 39/1034 | 371/18723 | 8.93e-05 | 2.07e-03 | 39 |
| GO:00512512 | Stomach | CSG | positive regulation of lymphocyte activation | 38/1034 | 362/18723 | 1.13e-04 | 2.42e-03 | 38 |
| GO:00508702 | Stomach | CSG | positive regulation of T cell activation | 26/1034 | 216/18723 | 1.57e-04 | 3.17e-03 | 26 |
| GO:00026962 | Stomach | CSG | positive regulation of leukocyte activation | 41/1034 | 409/18723 | 1.69e-04 | 3.33e-03 | 41 |
| GO:00160642 | Stomach | CSG | immunoglobulin mediated immune response | 25/1034 | 207/18723 | 1.98e-04 | 3.82e-03 | 25 |
| GO:00224092 | Stomach | CSG | positive regulation of cell-cell adhesion | 31/1034 | 284/18723 | 2.35e-04 | 4.37e-03 | 31 |
| GO:19030372 | Stomach | CSG | regulation of leukocyte cell-cell adhesion | 35/1034 | 336/18723 | 2.40e-04 | 4.43e-03 | 35 |
| GO:00197242 | Stomach | CSG | B cell mediated immunity | 25/1034 | 210/18723 | 2.48e-04 | 4.52e-03 | 25 |
| GO:00508672 | Stomach | CSG | positive regulation of cell activation | 41/1034 | 420/18723 | 2.96e-04 | 5.09e-03 | 41 |
| GO:19030392 | Stomach | CSG | positive regulation of leukocyte cell-cell adhesion | 27/1034 | 239/18723 | 3.36e-04 | 5.65e-03 | 27 |
| GO:00508632 | Stomach | CSG | regulation of T cell activation | 34/1034 | 329/18723 | 3.38e-04 | 5.66e-03 | 34 |
| GO:00024492 | Stomach | CSG | lymphocyte mediated immunity | 33/1034 | 350/18723 | 1.96e-03 | 2.06e-02 | 33 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
| hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
| hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
| hsa0541623 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
| hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
| hsa0532321 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
| hsa0494014 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
| hsa0533012 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
| hsa0533210 | Breast | IDC | Graft-versus-host disease | 11/867 | 42/8465 | 2.66e-03 | 1.80e-02 | 1.35e-02 | 11 |
| hsa0514012 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
| hsa0532010 | Breast | IDC | Autoimmune thyroid disease | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
| hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
| hsa0461233 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
| hsa0414532 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
| hsa0541633 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
| hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
| hsa0532331 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
| hsa0494015 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
| hsa0533013 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
| hsa0533211 | Breast | IDC | Graft-versus-host disease | 11/867 | 42/8465 | 2.66e-03 | 1.80e-02 | 1.35e-02 | 11 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Breast | DCIS |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Breast | Healthy |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Breast | IDC |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Cervix | ADJ |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Cervix | CC |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Cervix | Healthy |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Cervix | Precancer |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | CRC | AD |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | CRC | ADJ |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | CRC | SER |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Endometrium | AEH |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Endometrium | EEC |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Endometrium | Healthy |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | HNSCC | ADJ |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | HNSCC | Healthy |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | HNSCC | OSCC |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | HNSCC | Precancer |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Liver | Healthy |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Liver | Precancer |
| HLA-DRB5 | CD4 | HLA-DRB5_CD4 | MHC-II | Lung | AAH |
| Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HLA-DRB5 | SNV | Missense_Mutation | novel | c.611T>C | p.Val204Ala | p.V204A | Q30154 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HLA-DRB5 | SNV | Missense_Mutation | novel | c.536N>G | p.Asn179Ser | p.N179S | Q30154 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| HLA-DRB5 | SNV | Missense_Mutation | c.430N>A | p.Leu144Met | p.L144M | Q30154 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| HLA-DRB5 | SNV | Missense_Mutation | novel | c.501N>T | p.Glu167Asp | p.E167D | Q30154 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HLA-DRB5 | SNV | Missense_Mutation | novel | c.330C>A | p.His110Gln | p.H110Q | Q30154 | protein_coding | deleterious(0.02) | benign(0.179) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| HLA-DRB5 | SNV | Missense_Mutation | c.37G>A | p.Ala13Thr | p.A13T | Q30154 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HLA-DRB5 | SNV | Missense_Mutation | novel | c.611T>G | p.Val204Gly | p.V204G | Q30154 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| HLA-DRB5 | SNV | Missense_Mutation | c.469G>A | p.Glu157Lys | p.E157K | Q30154 | protein_coding | tolerated(0.41) | probably_damaging(0.998) | TCGA-37-3789-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HLA-DRB5 | SNV | Missense_Mutation | novel | c.154N>T | p.Arg52Trp | p.R52W | Q30154 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3127 | HLA-DRB5 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | amoxicillin | AMOXICILLIN | 10535882 | |
| 3127 | HLA-DRB5 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | 1D09C3 | 1D09C3 | ||
| 3127 | HLA-DRB5 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | clozapine | CLOZAPINE | 11146763 | |
| 3127 | HLA-DRB5 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | clavulanate | CLAVULANIC ACID | 10535882 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |